{
    "nct_id": "NCT03899246",
    "official_title": "Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease",
    "inclusion_criteria": "* A diagnosis of either Sickle Cell Disease with genotype SS or S Beta-zero, or SC disease.\n* Must have recurrent sites of pain, where majority of acute pain episodes are localized\n* Subjects are willing and able to comply with scheduled visits, treatment plan, laboratory tests, pain assessments, and other study procedures.\n* Subjects who are being treated with hydroxyurea (HU) must have been on a stable dose for at least 8 weeks prior to Visit 1 (Day 0), with the intent of remaining on the same dose of hydroxyurea throughout the clinical trial including the protocol-specified follow-up period unless adjustments are medically necessary due to bone marrow suppression.\n* At least 80% compliance (defined as logging pain at least once daily) with mobile application use during 14-day lead in period from time of enrollment to time of first capsaicin application.\nHealthy volunteers allowed\nMust have minimum age of 14 Years\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Age less than 14 or greater than 21\n* History of major surgery within the past 3 months.\n* Patients receiving scheduled chronic partial exchange transfusions as part of their sickle cell disease management protocol.\n* Concurrently taking another medication used in the treatment of neuropathic pain or with the potential to affect the peripheral nervous system (e.g. gabapentin, anti-epileptics, antidepressants, systemic alpha or beta adrenergic receptor blockers)\n* Use of another topical analgesic at home in the treatment of pain episodes such as topical lidocaine, diclofenac, or menthol (must discontinue use at the time of enrollment).\n* Recurrent pain secondary to an underlying condition other than vaso-occlusive pain (avascular necrosis, scoliosis, fracture, etc.)\n* Patients lacking the mental capacity to assent to the study\n* Patients with another chronic inflammatory/immune disorder that could skew the inflammatory markers listed above.\n* Pregnant females\n* Expectation that the subject will not be able to be followed for the duration of the study\n* Active use of illicit drugs and/or alcohol dependence, as determined by the investigator. Opioid use beyond the amount necessary for pain related to the underlying sickle cell disease as determined by the investigator.\n* Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator.",
    "miscellaneous_criteria": ""
}